IP Library › Granted Patent US 12,351,619
Granted Patent B2
US 12,351,619 · App. 17/786,786 · Granted Jul 8, 2025

Serum albumin-binding fibronectin type III domains and uses thereof

Inventors: Karyn O'Neil (Philadelphia, PA); Yao Xin (Philadelphia, PA); Russell C. Addis (Philadelphia, PA)
Assignee: ARO Biotherapeutics Company
C07K14/765C07K14/78C12N15/63G01N33/49C07K2319/21C07K2319/55C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,619
App. No.
17/786,786
Granted
Jul 8, 2025
Kind
B2
Abstract

Fibronectin type III domains (FN3) that bind to serum albumin, related polynucleotides capable of encoding serum albumin-binding FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

Claims (38)

1. A protein comprising an amino acid sequence that is at least 85% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, and 69.

2. The protein of claim 1 , wherein the protein comprises a substitution at a position that corresponds to residue position 10 of SEQ ID NO: 51.

3. The protein of claim 2 , wherein the substitution is selected from the group consisting of A10V, A10G, A10L, A10I, A10T, and A10S.

4. The protein of claim 1 , wherein the protein comprises a substitution selected from A10V, N33A, A35S, W37A, P39A, G40A, 141A, G42A, W47A, R49A, K69A, W71A, H73A, A79S, S80A, P82A, 185A, R87A, or combinations thereof, corresponding to SEQ ID NO: 51.

5. The protein of claim 1 , wherein the protein comprises a substitution at a position selected from 10, 33, 25, 37, 39, 40, 41, 42, 47, 49, 69, 71, 73, 79, 80, 82, 85, 87, or combinations thereof, of SEQ ID NO: 51.

6. The protein of claim 1 , wherein the protein is linked to another molecule.

7. The protein of claim 6 , wherein the another molecule is a drug, a protein, an antibody, a polymer, or a toxin.

8. The protein of claim 6 , wherein the another molecule is a FN3 domain that binds to a molecule other than human albumin.

9. The protein of claim 8 , wherein the FN3 domain binds to CD71.

10. The protein of claim 6 , wherein the protein is linked through a linker to the another molecule.

11. The protein of claim 10 , wherein the linker is a peptide linker comprising a sequence selected from (GS) 2 , (SEQ ID NO: 71), (GGGS) 2 (SEQ ID NO: 72), (GGGGS) 5 (SEQ ID NO: 73), (AP) 2 (SEQ ID NO: 74), (AP) 5 (SEQ ID NO: 75), (AP) 10 (SEQ ID NO: 76), (AP) 20 (SEQ ID NO: 77) or A (EAAAK) 5 AAA (SEQ ID NO: 78).

12. The protein of claim 1 , wherein the protein comprises an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, and 69.

13. The protein of claim 1 , wherein the protein comprises an amino acid sequence that is at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, and 69.

14. The protein of claim 13 , wherein the protein comprises a cysteine substitution in at least one residue position selected from 6, 11, 22, 25, 26, 52, 53, 61, 88, or combinations thereof, corresponding to the residue positions of SEQ ID NO: 1.

15. The protein of claim 13 , wherein the protein comprises a cysteine at the N and/or C-terminus of the protein.

16. The protein of claim 13 , wherein the protein is linked to another molecule.

17. The protein of claim 16 , wherein the another molecule is a drug, a protein, an antibody, a polymer, a toxin, or a FN3 domain that binds to a molecule other than human albumin.

18. The protein of claim 17 , wherein the FN3 domain binds to CD71.

19. The protein of claim 16 , wherein the protein is linked through a linker to the another molecule, and wherein the linker is a peptide linker comprising a sequence selected from (GS) 2 , (SEQ ID NO: 71), (GGGS) 2 (SEQ ID NO: 72), (GGGGS) 5 (SEQ ID NO: 73), (AP) 2 (SEQ ID NO: 74), (AP) 5 (SEQ ID NO: 75), (AP) 10 (SEQ ID NO: 76), (AP) 20 (SEQ ID NO: 77) or A (EAAAK) 5 AAA (SEQ ID NO: 78).

20. The protein of claim 1 , wherein the protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 51.

21. The protein of claim 1 , wherein the protein comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 51.

22. The protein of claim 21 , wherein the protein comprises a cysteine substitution in at least one residue position selected from 6, 11, 22, 25, 26, 52, 53, 61, 88, or combinations thereof, corresponding to the residue positions of SEQ ID NO: 1.

23. The protein of claim 1 , wherein the protein comprises an amino acid sequence that is at least 98% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, and 69.

24. The protein of claim 23 , wherein the protein comprises a cysteine substitution in at least one residue position selected from 6, 11, 22, 25, 26, 52, 53, 61, 88, or combinations thereof, corresponding to the residue positions of SEQ ID NO: 1.

25. The protein of claim 23 , wherein the protein is linked to another molecule.

26. The protein of claim 25 , wherein the another molecule is a drug, a protein, an antibody, a polymer, a toxin, or a FN3 domain that binds to a molecule other than human albumin.

27. The protein of claim 26 , wherein the FN3 domain binds to CD71.

28. The protein of claim 25 , wherein the protein is linked through a linker to the another molecule, and wherein the linker is a peptide linker comprising a sequence selected from (GS) 2 , (SEQ ID NO: 71), (GGGS) 2 (SEQ ID NO: 72), (GGGGS) 5 (SEQ ID NO: 73), (AP) 2 (SEQ ID NO: 74), (AP) 5 (SEQ ID NO: 75), (AP) 10 (SEQ ID NO: 76), (AP) 20 (SEQ ID NO: 77) or A (EAAAK) 5 AAA (SEQ ID NO: 78).

29. A protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, and 69.

30. A protein comprising the amino acid sequence of SEQ ID NO: 51.

31. The protein of claim 29 , wherein the protein is linked to another molecule.

32. The protein of claim 31 , wherein the another molecule is a drug, a protein, an antibody, a polymer, a toxin, or a FN3 domain that binds to a molecule other than human albumin.

33. The protein of claim 32 , wherein the FN3 domain binds to CD71.

34. The protein of claim 31 , wherein the protein is linked through a linker to the another molecule, and wherein the linker is a peptide linker comprising a sequence selected from (GS) 2 , (SEQ ID NO: 71), (GGGS) 2 (SEQ ID NO: 72), (GGGGS) 5 (SEQ ID NO: 73), (AP) 2 (SEQ ID NO: 74), (AP) 5 (SEQ ID NO: 75), (AP) 10 (SEQ ID NO: 76), (AP) 20 (SEQ ID NO: 77) or A (EAAAK) 5 AAA (SEQ ID NO: 78).

35. An isolated polynucleotide encoding the proteins of claim 1 .

36. A vector comprising the polynucleotide of claim 35 .

37. An isolated host cell comprising the vector of claim 36 .

38. A pharmaceutical composition comprising the protein of claim 13 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2022
From: O'NEIL, KARYN; XIN, YAO; ADDIS, RUSSELL C.
To: ARO BIOTHERAPEUTICS COMPANY
Reel/Frame 062159/0784 →
Continuity (2)
Provisional Application 62949856 · Dec 18, 2019
Related Publication 20230039851A1 · Feb 9, 2023
References Cited (132)
US RE30985E · Cartaya · 1982 [cited by applicant]
US 4560655A · Baker · 1985 [cited by applicant]
US 4657866A · Kumar · 1987 [cited by applicant]
US 4767704A · Cleveland et al. · 1988 [cited by applicant]
US 4927762A · Darfler · 1990 [cited by applicant]
US 5122469A · Mather et al. · 1992 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5643768A · Kawasaki · 1997 [cited by applicant]
US 5856456A · Whitlow et al. · 1999 [cited by applicant]
US 6172197B1 · McCafferty et al. · 2001 [cited by applicant]
US 6472147B1 · Janda et al. · 2002 [cited by applicant]
US 6582915B1 · Griffiths et al. · 2003 [cited by applicant]
US 6673901B2 · Koide · 2004 [cited by applicant]
US 6969108B2 · Fukumoto et al. · 2005 [cited by applicant]
US 7842476B2 · McGregor et al. · 2010 [cited by applicant]
US 8278419B2 · Jacobs et al. · 2012 [cited by applicant]
US 8569227B2 · Jacobs · 2013 [cited by applicant]
US 9644023B2 · Torres et al. · 2017 [cited by applicant]
US 10662235B2 · Anderson et al. · 2020 [cited by applicant]
US 10925932B2 · Diem et al. · 2021 [cited by applicant]
US 20040253247A1 · Dennis et al. · 2004 [cited by applicant]
US 20050287153A1 · Dennis · 2005 [cited by applicant]
US 20100216708A1 · Jacobs et al. · 2010 [cited by applicant]
US 20110118144A1 · Hyun et al. · 2011 [cited by applicant]
US 20110274623A1 · Jacobs · 2011 [cited by applicant]
US 20130079243A1 · Diem et al. · 2013 [cited by applicant]
US 20130226834A1 · Gannalo, II · 2013 [cited by applicant]
US 20150152147A1 · Gosselin et al. · 2015 [cited by applicant]
US 20150210756A1 · Torres et al. · 2015 [cited by applicant]
US 20160041182A1 · Diem et al. · 2016 [cited by applicant]
US 20170174748A1 · Mitchell et al. · 2017 [cited by applicant]
US 20170348397A1 · Diem et al. · 2017 [cited by applicant]
US 20190127444A1 · Brezski et al. · 2019 [cited by applicant]
US 20190256575A1 · Chen et al. · 2019 [cited by applicant]
US 20190263915A1 · Goldberg et al. · 2019 [cited by applicant]
US 20190330361A1 · Chin et al. · 2019 [cited by applicant]
US 20210228688A1 · Diem et al. · 2021 [cited by applicant]
CN 102307896A · 2012 [cited by applicant]
CN 103002923A · 2013 [cited by applicant]
CN 103827361A · 2014 [cited by applicant]
CN 104955473A · 2015 [cited by applicant]
JP 2012507295A · 2012 [cited by applicant]
WO 1987000195A1 · 1987 [cited by applicant]
WO 1990003430A1 · 1990 [cited by applicant]
WO 9013646A1 · 1990 [cited by applicant]
WO 9411026A3 · 1994 [cited by applicant]
WO 0034317 · 2000 [cited by applicant]
WO 2004003019A2 · 2004 [cited by applicant]
WO 2009085462A1 · 2009 [cited by applicant]
WO 2010051274A2 · 2010 [cited by applicant]
WO 2010093627A2 · 2010 [cited by applicant]
WO 2011140086A2 · 2011 [cited by applicant]
WO 2011150133A2 · 2011 [cited by applicant]
WO 2013049275A1 · 2013 [cited by applicant]
WO 2013177398A2 · 2013 [cited by applicant]
WO 2014081944A2 · 2014 [cited by applicant]
WO 2014530014A · 2014 [cited by applicant]
WO 2015089073A2 · 2015 [cited by applicant]
WO 2015143199A1 · 2015 [cited by applicant]
WO 2016197071A1 · 2016 [cited by applicant]
WO 2017210425A1 · 2017 [cited by applicant]
WO 2017223180A2 · 2017 [cited by applicant]
WO 2018052828A1 · 2018 [cited by applicant]
WO 2018111973A1 · 2018 [cited by applicant]
WO 2021127353A1 · 2021 [cited by applicant]
Koide, et al. The Fibronectin Type III Domain as a Scaffold for Novel Binding Proteins, J. Mol. Biol. (1998) 284, pp. 1141-1151. [cited by applicant]
Extended European Search Report dated Dec. 21, 2023. [cited by applicant]
Alfthan, et al., “Properties of a single-chain antibody containing different linker peptides,” Protein Engineering, 8(7): 725-731 (1995). [cited by applicant]
Altuvia et al., “Ranking Potential Binding Peptides to MHC Molecules by a Computational Threading Approach”, Journal of Molecular Biology, vol. 249, Issue 2, pp. 244-250, 1995. [cited by applicant]
Andersen et al., “Extending Half-life by Indirect Targeting of the neonatal Fe Receptor (FcRn) Using a Minimal Albumin Binding Domain”, Journal of Biological Chemistry, vol. 286, No. 7, pp. 5234-5241, 2011. [cited by applicant]
Barnes et al., “Methods for growth of cultured cells in serum-free medium” Analytical Biochemistry, vol. 102, Issue 2, pp. 255-270, Mar. 1980. [cited by applicant]
Binz et al., “High-affinity binders selected from designed ankyrin repeat protein libraries,” Nature Biotechnology, vol. 22, No. 5, pp. 575-585 (May 2004). [cited by applicant]
Birtalan et al., “The Intrinsic Contributions of Tyrosine, Serine, Glycine and Arginine to the Affinity and Specificity of Antibodies”, Journal of Molecular Biology, vol. 377, Issue 5, pp. 1518-1528, Apr. 2008. [cited by applicant]
Bork et al., “Proposed acquisition of an animal protein domain by bacteria”, Proc. Natl. Acad, Sci, vol. 89, pp. 8990-8994, Oct. 1992. [cited by applicant]
Breton et al., “Prolonged Half-Life in the Circulation of a Chemical Conjugate Between a Pro-Urokinase Derivative and Human Serum Albumin”, Eur. J. Biochem., vol. 231, pp. 563-569, 1995. [cited by applicant]
Connell, “Expression Systems for use in actinomycetes and related organisms”, Curr. Opin. Biotechnol., vol. 12, pp. 446-449, 2001. [cited by applicant]
Coppieters et al., “Formatted Anti-Tumor necrosis Factor a VHH Proteins Derived From Camelids Show Superior Potency and Targeting to inflamed Joints in a Murine Model of Collagen-Induced Arthritis”, Arthritis & Rheumati… [cited by applicant]
Database Geneseq (online) Aug. 13, 2015 (Aug. 13, 2015), “Staphylococcal leukotoxin binding FN3 domain (Luk122), Seq Id 145”, XP055768899, retrieved from EBI accession No. GSP:BCB11489 Database accession No. BCB11489 (1… [cited by applicant]
Database Geneseq, “Staphylococcal LukE binding FN3 domain (Luk51), Seq Id 50”, XP002796459, EBI accession No. GSP:BCB11394, *sequence*, (2015). (2 pages). [cited by applicant]
David et al., “Protein iodination with solid state lactoperoxidase” Biochemistry, vol. 13, No. 5, pp. 1014-1021, 1974. [cited by applicant]
Dennis “Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins”, Journal of Biological Chemistry, vol. 277, No. 38, pp. 35035-35043, 2002. [cited by applicant]
Dennis et al., “Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting Agent”, Cancer Research, vol. 67, pp. 254-261, Jan. 2007. [cited by applicant]
Duttaroy et al., “Development of a Long-Acting Insulin Analog Using Albumin Fusion Technology”, Diabetes, vol. 54, pp. 251-258, Jan. 2005. [cited by applicant]
Final Office Action for U.S. Appl. No. 15/611,296 dated Aug. 4, 2020. [cited by applicant]
Flisiak et al., “Albinterferon-alfa 2b: a new treatment option for hepatitis C”, Expert Opinion on Biological therapy, vol. 10, issue 10, pp. 1509-1515, 201 O. [cited by applicant]
Hallewell et al., “Genetically engineered Polymers of Human CuZn Superoxide Dismutase”, Journal of Biological Chemistry, vol. 264, No. 9, pp. 5260-5268, 1989. [cited by applicant]
Ham et al., “Media and growth requirements”, Methods in Enzymology, vol. 58, pp. 44-93, 1979. [cited by applicant]
Hanes et al., “In vitro selection and evolution of the functional proteins by using ribosome display”, Proc Natl. Acad. Sci,. USA, vol. 94, pp. 4937-4942, May 1997. [cited by applicant]
Holt et al., “Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs”, Protein Engineering Design & Selection, vol. 21, No. 5, pp. 283-288, 2008. [cited by applicant]
Hunter, “Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity”, Nature, vol. 194, 1962. [cited by applicant]
International Preliminary Report on Patentability for PCTUS2017035442 dated Dec. 4, 2018. [cited by applicant]
International Preliminary Report on Patentability for PCTUS2020065878 dated May 17, 2022. [cited by applicant]
International Search Report and Written Opinion for PCTUS2017035442 dated Aug. 11, 2017. [cited by applicant]
International Search Report and Written Opinion for PCTUS2020065878 dated Mar. 31, 2021. [cited by applicant]
Jacobs et al., “Design of novel FN3 domains with high stability by a consensus sequence approach”, Protein Engineering Design & Selection, vol. 25, No. 3,, pp. 107-117, 2012. [cited by applicant]
Jacobs Sa et al, “Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics”, Protein Engineering, Design and Selection, Oxford Journal, London, GB, vol. 28, No. 10, doi: 10.1093/PRO… [cited by applicant]
Koide et al., “High-affinity single-domain binding proteins with a binary-code interface,” PNAS, vol. 104, No. 16, pp. 6632-6637 (Apr. 17, 2007). [cited by applicant]
Koide, et al., “Teaching an Old Scaffold New Tricks: Monobodies Constructed Using Alternative Surfaces of the FN3 Scaffold”, Journal of Molecular Biology, Academic Press, vol. 415, No. 3, pp. 393-405 (2011). [cited by applicant]
Kontermann et al., “Strategies for extended serum half-lite of protein therapeutics” Current Opinion in Biotechnology, vol. 22, pp. 868-876, 2011. [cited by applicant]
Lehmann et al., “Engineering proteins for theromostability: the use of sequence alignments versus rational design and directed evolution”, Current Opinion in Biotechnology, vol. 12, pp. 371-375, 2001. [cited by applicant]
Luckow et al., “Trends in the Development of Baculovirus Expression Vetors”, Biotechnology, vol. 6, pp. 47-55, 1988. [cited by applicant]
Makrides “Strategies for Achieving High-Level Expression of Genes in [cited by applicant]
Malm et al., “Engineering of bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension”, Biotechnology Journal, vol. 9, … [cited by applicant]
Mayfield et al., Expression and assembly of a fully active antibody in algae, PNAS, vol. 100, No. 2, pp. 438-442, Jan. 2003. [cited by applicant]
Meinke, et al., “Cellulose-Binding Polypeptides from Cellulomonas fimi: Endoglucanase D (CenD), a Family A ˜- 1,4-Glucanase,” Journal of Bacteriology, 175(7): 1910-1918 (1993). [cited by applicant]
Metzner et al., “Genetic fusion to albumin improves the pharmacokinetic properties of factor IX”, Thromb. Haemost. vol. 102, pp. 634-644, 2009. [cited by applicant]
Muller et al., “Improved Pharmacokinetics of Recombinant bispecific Antibody Molecules by Fusion to Human Serum Albumin”, Journal of Biological Chemistry, vol. 282, No. 17, p. 12650-12660, Apr. 2007. [cited by applicant]
Muller et al., “Superior serum half life of albumin tagged TNF ligands”, Biochemical and Biophysical Research Communications, vol. 396, pp. 793-799, 2010. [cited by applicant]
Non Final Office Action for U.S. Appl. No. 15/611,296 dated Aug. 6, 2019. [cited by applicant]
Non Final Office Action for U.S. Appl. No. 15/611,296 dated Feb. 6, 2020. [cited by applicant]
Non Final Office Action for U.S. Appl. No. 17/153,229 dated Apr. 5, 2023. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/611,296 dated Oct. 21, 2020. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/153,229 dated Jul. 28, 2023. [cited by applicant]
Nygren, “Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents”, Journal of Histochemistry and Cytochemistry, vol. 30, No. 5, pp. 407-412, 1… [cited by applicant]
Odegrip et al., “CIS display: In vitro selection of peptides from libraries of protein-DNA complexes”, Proc Natl Acad Sci USA, vol. 101, No. 9, pp. 2806-2810, Mar. 2004. [cited by applicant]
Olson et al., “Design, expression, and stability of a diverse protein library based on the human fibronectin type III domain”, Protein Science, vol. 16, No. 3, pp. 476-484, 2007. [cited by applicant]
Orlova et al., “Site-Specific Radiometal labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein”, J. Nucl Med, vol. 54, No. 6, pp. 961-968, Ju… [cited by applicant]
Osborn et al., “Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys”, European Journal of Pharmacology, vol. 456, pp. 149-158, 2002. [cited by applicant]
Pain et al., “Preparation of Protein A-Peroxidase monoconjugate Using a Heterobifunctional Reagent, and its use in Enzyme Immunoassays”, Journal of Immunological Methods, vol. 40, pp. 219-230, 1981. [cited by applicant]
Raju et al., “Glycoengineering of Therapeutic Glycoproteins: In Virto Galactosylation and Sialylation of Glycoproteins with Terminal N-Acetylglucosamine and Galactose Residues”, Biochemistry, vol. 40, pp. 8868-8876, 200… [cited by applicant]
Roberts et al., “RNA-peptide fusions for the in vitro selection of peptides and proteins”, Proc. Natl. Acad Sci, USA. vol. 94, pp. 12297-12302, Nov. 1997. [cited by applicant]
Robinson, et al., “Covalent Attachment of Arc Repressor Subunits by a Peptide Linker Enhances Affinity for Operator DNA,” Biochemistry, 35: 109-116 (1996). [cited by applicant]
Schulte “Use of albumin fusion technology to prolong the half-life of recombinant factor Vila”, Thrombosis Research, 122, Suppl. 4, pp. S14-S19, 2008. [cited by applicant]
Sharp et al., “Synonymous codon usage in [cited by applicant]
Sheffield et al., “Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris” Blood Coagulation and Fibrinolysis, vol. 12, pp. 433-443, 2001. [cited by applicant]
Sinclair et al., “Synonymous codon usage bias and the expression of human glucocerebrosidase in the methylotrophic yeast, Pichia pastoris”, Protein Expression and Purification, vol. 26, pp. 96-105, 2002. [cited by applicant]
Tijink et al., “Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular Nanobody technology”, Mol Cancer Ther, 7(8), pp. 2288-2297, 2008. [cited by applicant]
Walker et al., “Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon”, Protein Engineering, Design & Selection, vol. 23, No. 4, pp. 271-278,2010. [cited by applicant]
Watanabe, et al., “Gene Cloning of Chitinase A 1 from Bacillus circulans WL-12 Revealed Its Evolutionary Relationship to Serratia Chitinase and to the Type III Homology United of Fibronectin,” The Journal of Biological … [cited by applicant]
Wunder et al., “Albumin-based Drug Delivery as Novel Therapeutic Approach for Rheumatoid Arthritis”, Journal of immunology, vol. 170, pp. 4 793-4801, 2003. [cited by applicant]
Zhang et al., “PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel”, Computer Methods and Programs in Biomedicine, vol. 99, pp. 306-314, 2010. [cited by applicant]
Zola, “Monoclonal Antibodies”, Encyclopedia of Life Sciences, vol. 9 pp. 14 7-158, 2010. [cited by applicant]